AstraZeneca Shares Voting Rights Update

AstraZeneca’s New Breast Cancer Treatment Nears EU Approval

Why UK Giants Should Think Twice Before Ditching London Listing

Earnings Slew: The Bloomberg Close, Europe Edition

London Stock Exchange Boss to Join Ranks of UK’s Highest Paid Execs

AstraZeneca Sees Strong Growth in Q1 2024

AstraZeneca’s Profit Gains on Sales of Cancer Drugs

How 4% Could Be the New Inflation Target

FTSE 100 Closes at a Record for First Time in More Than a Year

FTSE 100 Closes at a Record for First Time Since February 2023

London Bankers Inch Closer to New York-Style Bumper Bonuses

Astrazeneca (AZN) Could Be a Great Choice

IMFINZI® (durvalumab) plus chemotherapy doubled overall survival rate at three years for patients with advanced biliary tract cancer in TOPAZ-1 Phase III trial

3 Pharma Stocks That Are Money-Printing Machines in 2024

The Market View on UK Stocks Is Slowly Shifting

AstraZeneca's (AZN) Fasenra Gets FDA Nod for Asthma in Kids

EU Probe Finds No Added Suicide Risk Linked to Novo’s Wegovy

Parkinson’s Patients Must Wait for One Drug That Could Help

A CEO's Pay Raises Massive Questions for London

Astrazeneca (AZN) Outperforms Broader Market: What You Need to Know